SRPT:NGS-Sarepta Therapeutics Inc. (USD)

EQUITY | Biotechnology | Nasdaq Global Select

Last Closing

USD 120.66

Change

+1.69 (+1.42)%

Market Cap

USD 1.99B

Volume

0.51M

Analyst Target

USD 193.38
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Sarepta Therapeutics Inc is a biopharmaceutical company focused on the discovery and development of RNA-targeted therapeutics for the treatment of rare, infectious and other diseases.

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-12-23 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap
VRTX Vertex Pharmaceuticals Inc

+8.00 (+2.01%)

USD 120.60B
REGN Regeneron Pharmaceuticals Inc

+13.28 (+1.89%)

USD 84.94B
ARGX argenx NV ADR

+4.50 (+0.72%)

USD 36.54B
ALNY Alnylam Pharmaceuticals Inc

-3.18 (-1.30%)

USD 31.66B
BGNE BeiGene Ltd

+1.20 (+0.68%)

USD 20.24B
UTHR United Therapeutics Corporatio..

+4.07 (+1.13%)

USD 16.18B
MRNA Moderna Inc

+0.20 (+0.51%)

USD 16.10B
RPRX Royalty Pharma Plc

+0.33 (+1.32%)

USD 15.27B
SMMT Summit Therapeutics PLC

+0.80 (+4.48%)

USD 13.67B
INCY Incyte Corporation

+1.00 (+1.45%)

USD 13.52B

ETFs Containing SRPT

MSGR 6.12 % 0.00 %

N/A

N/A
CURE:XETRA VanEck Genomics and Healt.. 5.11 % 0.00 %

-0.09 (-0.09%)

N/A
XDNA:CA iShares Genomics Immunolo.. 4.29 % 0.00 %

+0.48 (+-0.09%)

CAD 5.33M
IDNA iShares Genomics Immunolo.. 4.21 % 0.00 %

+0.15 (+-0.09%)

USD 0.12B
GNOG:LSE Global X Genomics & Biote.. 4.04 % 0.00 %

+0.01 (+-0.09%)

USD 9.08M
GNOM Global X Genomics & Biote.. 4.04 % 0.00 %

+0.03 (+-0.09%)

USD 0.07B
GN0M:XETRA Global X Genomics & Biote.. 4.03 % 0.00 %

-0.04 (-0.09%)

USD 7.05M
GNOM:SW Global X Genomics & Biote.. 4.03 % 0.00 %

N/A

USD 9.83M
IBRN iShares Trust - iShares N.. 3.89 % 0.00 %

+0.24 (+-0.09%)

USD 3.86M
PINK Simplify Exchange Traded .. 3.78 % 0.00 %

+0.08 (+-0.09%)

USD 0.15B
CURG:LSE VanEck Genomics and Healt.. 3.67 % 0.00 %

-0.01 (-0.09%)

USD 5.35M
BIOT:SW L&G Pharma Breakthrough U.. 3.00 % 0.00 %

-0.01 (-0.09%)

N/A
CURE:AU ETFS S&P Biotech ETF 2.70 % 0.00 %

+1.23 (+-0.09%)

USD 0.04B
LABU Direxion Daily S&P Biotec.. 1.81 % 1.14 %

+1.82 (+-0.09%)

USD 0.82B
WDNA:LSE WisdomTree BioRevolution .. 1.73 % 0.00 %

-0.07 (-0.09%)

N/A
HAPY Harbor Corporate Culture .. 1.49 % 0.00 %

+0.09 (+-0.09%)

USD 0.01B
THNZ:XETRA L&G Global Thematic ESG E.. 0.80 % 0.00 %

-0.05 (-0.09%)

N/A
IQSM Iq Candriam ESG U.S. Mid .. 0.77 % 0.00 %

+0.06 (+-0.09%)

N/A
AGED:SW iShares Ageing Population.. 0.68 % 0.00 %

N/A

N/A
USSMC:SW UBS (Irl) ETF plc - MSCI .. 0.60 % 0.00 %

+0.78 (+-0.09%)

N/A
H41G:XETRA HSBC MSCI World Small Cap.. 0.39 % 0.00 %

-0.16 (-0.09%)

N/A
BTAL AGFiQ U.S. Market Neutral.. 0.00 % 0.00 %

-0.09 (-0.09%)

N/A
LABS 0.00 % 0.45 %

N/A

N/A
BTEC 0.00 % 0.42 %

N/A

N/A
AGED:LSE iShares Ageing Population.. 0.00 % 0.00 %

+0.04 (+-0.09%)

N/A
AGES:LSE iShares IV Public Limited.. 0.00 % 0.00 %

-0.13 (-0.09%)

N/A
BIGT:LSE L&G Pharma Breakthrough U.. 0.00 % 0.00 %

-5.05 (-0.09%)

N/A
XBI SPDR® S&P Biotech ETF 0.00 % 0.35 %

+0.61 (+-0.09%)

N/A
DRDR:LSE iShares Healthcare Innova.. 0.00 % 0.00 %

-0.25 (-0.09%)

N/A
HEAL:LSE iShares Healthcare Innova.. 0.00 % 0.00 %

-0.03 (-0.09%)

N/A
WLDS:LSE iShares MSCI World Small .. 0.00 % 0.00 %

-0.02 (-0.09%)

N/A
WSML:LSE iShares MSCI World Small .. 0.00 % 0.00 %

-0.08 (-0.09%)

N/A
ETLI:F Legal & General UCITS ETF.. 0.00 % 0.00 %

+0.03 (+-0.09%)

N/A
BMED BlackRock Future Health E.. 0.00 % 0.00 %

-0.01 (-0.09%)

USD 4.16M
DWEQ 0.00 % 0.00 %

N/A

N/A

Market Performance

  Market Performance vs. Industry/Classification (Biotechnology) Market Performance vs. Exchange (Nasdaq Global Select)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 25.13% 77% C+ 78% C+
Dividend Return N/A N/A N/A N/A N/A
Total Return 25.13% 77% C+ 77% C+
Trailing 12 Months  
Capital Gain 27.63% 76% C+ 79% B-
Dividend Return N/A N/A N/A N/A N/A
Total Return 27.63% 76% C+ 78% C+
Trailing 5 Years  
Capital Gain -10.16% 74% C 47% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -10.16% 74% C 40% F
Average Annual (5 Year Horizon)  
Capital Gain 25.16% 67% D+ 77% C+
Dividend Return 25.16% 67% D+ 76% C+
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 118.24% 35% F 19% F
Risk Adjusted Return 21.28% 77% C+ 54% F
Market Capitalization 1.99B 98% N/A 93% A

Key Financial Ratios

  Ratio vs. Industry/Classification (Biotechnology) Ratio vs. Market (Nasdaq Global Select)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio 80.86 11% 14%
Price/Book Ratio 9.68 16% 14%
Price / Cash Flow Ratio -23.59 92% 90%
Price/Free Cash Flow Ratio 64.19 2% 6%
Management Effectiveness  
Return on Equity 12.27% 96% 82%
Return on Invested Capital -14.09% 80% 37%
Return on Assets 1.51% 95% 71%
Debt to Equity Ratio 131.79% 16% 17%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

Superior return on assets

The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior capital utilization

The company management has delivered better return on invested capital in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior return on equity

The company management has delivered better return on equity in the most recent 4 quarters than its peers, placing it in the top quartile.

High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

High Gross Profit to Asset Ratio

This stock is in the top quartile compared to its peers on Gross Profit to Asset Ratio. This is a popular measure among value investors for showing superior returns in the long run.

What to not like:
Highly leveraged

The company is in the bottom half compared to its sector peers on debt to equity and is highly leveraged. However, do check the news and look at its sector and management statements. Sometimes this is high because the company is trying to grow aggressively.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Overpriced compared to earnings

The stock is trading high compared to its peers on a price to earning basis and is above the sector median.

High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Overpriced on free cash flow basis

The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.